These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464 [TBL] [Abstract][Full Text] [Related]
12. Tuberculosis: clinical trials and new drug regimens. Kwon YS; Jeong BH; Koh WJ Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239 [TBL] [Abstract][Full Text] [Related]
13. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883 [TBL] [Abstract][Full Text] [Related]
14. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637 [TBL] [Abstract][Full Text] [Related]
16. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568 [TBL] [Abstract][Full Text] [Related]
17. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695 [TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. Ge F; Zeng F; Liu S; Guo N; Ye H; Song Y; Fan J; Wu X; Wang X; Deng X; Jin Q; Yu L J Med Microbiol; 2010 May; 59(Pt 5):567-572. PubMed ID: 20075118 [TBL] [Abstract][Full Text] [Related]
19. Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species. Howell M; Wirz D; Daniels AU; Braissant O J Clin Microbiol; 2012 Jan; 50(1):16-20. PubMed ID: 22090404 [TBL] [Abstract][Full Text] [Related]
20. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A mBio; 2010 Aug; 1(3):. PubMed ID: 20802826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]